Oregon Health & Science University is participating in a national study of a drug that may prevent Alzheimer’s disease by blocking an enzyme that produces plaques believed to trigger the disorder. OHSU is one of six sites around the country taking part in a double-blind, placebo-controlled study of the agent known as LY450139, a gamma secretase inhibitor manufactured by Indianapolis-based Eli Lilly and Co. Other study sites are in Indianapolis, St. Louis, Philadelphia, Seattle, and La Jolla, Calif. Lilly is funding the study.
